Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Apogee Therapeutics, Inc. - Common Stock Market Cap
The Apogee Therapeutics, Inc. - Common Stock (APGE) share price is expected to increase by 50.4% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered APGE. Price targets range from $75 at the low end to $95 at the high end. The current analyst consensus for APGE is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned APGE 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Apogee Therapeutics, Inc. - Common Stock to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on APGE. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of APGE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Geoff Meacham B of A Securities | Buy | $80 | Initiates | May 10, 2024 |
| Akash Tewari Jefferies | Buy | $75 | Maintains | Mar 6, 2024 |
| Akash Tewari Stifel | Buy | $95 | Maintains | Mar 5, 2024 |
| Seamus Fernandez Guggenheim | Buy | $91 | Maintains | Mar 5, 2024 |
| Seamus Fernandez Guggenheim | Buy | $44 | Maintains | Jan 3, 2024 |
| Julian Harrison BTIG | Buy | $43 | Initiates | Dec 20, 2023 |
| David Nierengarten Wedbush | Outperform | $40 | Initiates | Aug 8, 2023 |
| Akash Tewari Jefferies | Buy | $29 | Initiates | Aug 8, 2023 |
| Seamus Fernandez Guggenheim | Buy | $29 | Initiates | Aug 8, 2023 |
| Tyler Van Buren TD Cowen | Outperform | Initiates | Aug 8, 2023 | |
| Akash Tewari Stifel | Buy | $34 | Initiates | Aug 8, 2023 |
When did it IPO
N/A
Staff Count
91
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Michael Thomas Henderson M.D.
Market Cap
$3.19B
In 2023, APGE generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that APGE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Apogee Therapeutics, Inc. (Nasdaq: APGE) will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on September 18, 2024, at 12:30 p.m. E.T.
Why It Matters - Apogee Therapeutics' participation in a prominent summit highlights its commitment to advancing treatments in significant markets, potentially impacting stock performance and investor interest.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Apogee Therapeutics appointed Jeff S. Hartness as Chief Commercial Officer. Hartness brings over 25 years of biotech experience in product launches and market strategy.
Why It Matters - The appointment of Jeff S. Hartness as CCO signals a strategic push for Apogee Therapeutics in commercializing its pipeline, potentially enhancing market positioning and investor confidence in future growth.
Mon, 19 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 trial for APG990, targeting atopic dermatitis. Results are expected in 2025, with a trial for APG777 and APG990 starting the same year.
Why It Matters - The announcement of Phase 1 trial data for APG990 and the upcoming trials for APG777 signals potential advancements in treatments for atopic dermatitis and other inflammatory diseases, impacting future revenues.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company is on track with its pipeline, expecting APG777 Phase 2 data in 2H 2025, APG808 Phase 1 data in 4Q 2024, and APG990 Phase 1 trial start in 3Q 2024.
Why It Matters - Timely clinical milestones can drive stock prices and investor confidence, indicating the company's progress in drug development and potential future revenue streams.
Tue, 18 Jun 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Apogee Therapeutics stock fell 34% post-buy recommendation, contrasting with a 7.7% S&P 500 rise. The firm raised $420M at $62/share and is advancing APG777 in Phase 2 trials for atopic dermatitis and asthma.
Why It Matters - Apogee Therapeutics' stock drop contrasts sharply with the S&P 500's gain, raising concerns. However, successful fundraising and promising trial results may boost future performance and investor confidence.
Tue, 28 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Apogee Therapeutics appointed Dr. Lisa Bollinger to its board. She has over 30 years in drug development and regulatory affairs, previously serving at Merck.
Why It Matters - Dr. Bollinger's appointment enhances Apogee's leadership with extensive regulatory expertise, potentially increasing investor confidence in successful drug development and approvals.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
